Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Interleukin Inhibitors Market Size, Value And Growth Trajectory Through 2030
The market size for interleukin inhibitors has experienced substantial growth in recent years. It is projected to expand from $57.87 billion in 2025 to $68.56 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 18.5%. Historically, this growth can be attributed to several factors, including the limited availability of interleukin inhibitors, an increasing prevalence of autoimmune diseases, heightened physician awareness and prescribing practices, continued reliance on conventional therapies, and the expansion of hospital pharmacies and specialty clinics.
The interleukin inhibitors market is anticipated to experience substantial growth over the next few years. It is predicted to reach $136.99 billion in 2030, growing at a compound annual growth rate (CAGR) of 18.9%. This expansion during the forecast period is driven by the development of next-generation biologics, increasing investment in personalized immunotherapies, the expansion of online pharmacies and telemedicine platforms, a rise in regulatory approvals for novel interleukin inhibitors, and growing government and healthcare initiatives focused on chronic disease management. Key trends for this period include the rising adoption of interleukin inhibitors for autoimmune disorders, the growth of biologic therapies targeting IL-17, IL-23, IL-1, IL-5, and IL-6, an increasing focus on personalized and targeted immunotherapies, the expansion of hospital and specialty clinic distribution channels, and the integration of telemedicine and digital platforms into chronic disease management.
Get A Free Sample Report With In-Depth Market Insights:
Interleukin Inhibitors Market Industry Drivers: What’s Behind The Revenue Growth?
The increasing occurrence of bacterial infections is anticipated to propel the interleukin inhibitors market moving ahead. Bacterial infections are illnesses stemming from bacteria, which are minute single-celled organisms. Interleukin inhibitors offer significant benefits in managing and averting bacterial diseases by inhibiting bacterial proliferation. As an illustration, in March 2024, data from the Centers for Disease Control and Prevention, a US-based government agency, indicated an escalation in tuberculosis cases from 8,320 in 2022 to 9,615 in 2023, marking an increase of 1,295 cases. Consequently, the growing prevalence of bacterial infections is a key driver for the interleukin inhibitors market.
Interleukin Inhibitors Market Segment Analysis And Revenue Potential
The interleukin inhibitors market covered in this report is segmented –
1) By Type: IL-17, IL-23, IL-1, IL-5, IL-6
2) By Application: Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Asthma, Inflammatory Bowel Disease, Other Applications
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By IL-17: Secukinumab, Ixekizumab, Brodalumab
2) By IL-23: Ustekinumab, Guselkumab, Tildrakizumab
3) By IL-1: Anakinra, Canakinumab
4) By IL-5: Mepolizumab, Reslizumab, Benralizumab
5) By IL-6: Tocilizumab, Sarilumab
#Interleukin Inhibitors Market Growth Trends: What’s Shaping The Future Outlook?
Companies operating in the interleukin inhibitors market are actively focusing on the development of innovative therapies, such as monoclonal antibody biosimilars, to improve treatment efficacy, reduce costs, and enhance patient accessibility. A monoclonal antibody biosimilar is defined as a biologic product that is highly similar to an already approved reference antibody, exhibiting no clinically meaningful differences in terms of safety or efficacy. For instance, in October 2025, Celltrion Inc., a biopharmaceutical company based in South Korea, launched its AVTOZMA (tocilizumab-anoh) intravenous (IV) formulation within the United States. This therapy targets interleukin-6 receptors to manage conditions like rheumatoid arthritis and other inflammatory disorders. The introduction of this treatment aims to improve patient access and clinical outcomes by expanding the availability of advanced biologic treatments.
Interleukin Inhibitors Market Key Players Shaping Industry Direction
Major companies operating in the interleukin inhibitors market are Sanofi S.A., GlaxoSmithKline plc, Novartis International AG, Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Eli Lilly and Company, AstraZeneca plc, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., AbbVie Inc., Sun Pharmaceutical Industries Limited, Boehringer Ingelheim International GmbH, Janssen Biotech Inc., Ortho Dermatologics, Amgen Inc., Celgene Corporation, Bristol-Myers Squibb Company, Pfizer Inc., Merck & Co. Inc., Takeda Pharmaceutical Company Limited, Biogen Inc., Incyte Corporation, Kyowa Kirin Co Ltd., Astellas Pharma Inc., Ipsen Biopharmaceuticals Inc.
View The Full Interleukin Inhibitors Market Report:
Interleukin Inhibitors Market Global Footprint: Which Region Leads The Market?
North America was the largest region in the interleukin inhibitors market in 2025. The regions covered in the interleukin inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
